A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and ...

Semaglutide appears to be protective against heart attacks and other cardiac events regardless of weight loss, research has ...

Semaglutide reduces the risk of heart attack, stroke, and other major cardiac events. | Drug Discovery And Development ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

The Company’s investigational small moleculeglucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss ...

Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much ...

Even when weight doesn’t drop much, the obesity-medication semaglutide still offers major heart-protection, research shows.

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in ...

Academics set out to examine the additional benefits of semaglutide, which is the main ingredient of Wegovy and also type 2 ...

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.